| 著者 |
Imaoka, Hiroshi
Ikeda, Masafumi
Kobayashi, Satoshi
Ohba, Akihiro
Ueno, Masayuki
Suzuki, Yuko
Tsumura, Hidetaka
Kimura, Nana
Kawaguchi, Shinya
Kawamoto, Yasuyuki
Nakachi, Kohei
Tsuji, Kunihiro
Kobayashi, Noritoshi
Ashida, Reiko
Okano, Naohiro
Umemoto, Kumiko
Murohisa, Gou
細川, 歩
WEKO
33635
e-Rad_Researcher
90432111
| ja |
細川, 歩
宮崎大学
|
| ja-Kana |
ホソカワ, アユム
|
| en |
Hosokawa, Ayumu
University of Miyazaki
|
Search repository
Asagi, Akinori
| en |
Asagi, Akinori
National Hospital Organization Shikoku Cancer Center
|
Search repository
Nebiki, Hiroko
Suzuki, Rei
Terashima, Takeshi
Shibata, Ryusuke
| en |
Shibata, Ryusuke
Kagoshima University Graduate School of Medical and Dental Sciences
|
Search repository
Kawata, Kazuhito
Doi, Toshifumi
Ohyama, Hiroshi
Kitano, Yohei
Shioji, Kazuhiko
Okuyama, Hiroyuki
Naganuma, Atsushi
| en |
Naganuma, Atsushi
National Hospital Organization Takasaki General Medical Center
|
Search repository
Negoro, Yuji
Sakamoto, Yasunari
| en |
Sakamoto, Yasunari
International University of Health and Welfare Atami Hospital
|
Search repository
Shimizu, Satoshi
Morizane, Chigusa
Ueno, Makoto
Furuse, Junji
Nagano, Hiroaki
| en |
Nagano, Hiroaki
Yamaguchi University Graduate School of Medicine
|
Search repository
|
|
内容記述 |
Background
S-1 monotherapy had previously been widely used as a second-line treatment for pancreatic cancer (PC) after gemcitabine-based chemotherapy mainly in Japan. Based on the results of the NAPOLI-1 trial, the recommended second-line therapy is now liposomal irinotecan plus fluorouracil/folinic acid (nal-IRI + 5-FU/LV). However, there have been no studies comparing nal-IRI + 5-FU/LV therapy with S-1 monotherapy.
Methods
The main objective of this study was to compare overall survival (OS) in patients treated with nal-IRI + 5-FU/LV and those treated with S-1 monotherapy as second-line treatments, using the inverse probability of treatment weighting (IPTW) method. This study was conducted in 31 institutions participating in Japan Oncology Network in Hepatobiliary and Pancreas. To minimize potential biases due to the retrospective design, IPTW analysis was performed with multiple imputation, and imputed IPTW-adjusted hazard ratios and corresponding 95% confidence intervals (CIs) were estimated using a Cox proportional hazards model and combined into pooled estimates.
Results
A total of 463 metastatic PC patients were enrolled in this study (257 in the S-1 monotherapy group and 206 in the nal-IRI + 5-FU/LV group). The median OS was 7.50 months (95% CI 4.18–12.69 months) in the nal-IRI + 5-FU/LV group and 5.72 months (95% CI 2.76–10.79 months) in the S-1 monotherapy group. In the IPTW-adjusted Cox proportional hazards model, nal-IRI + 5-FU/LV was associated with a significant OS benefit (pooled IPTW-adjusted hazard ratio, 0.779; 95% CI 0.399—0.941; p = 0.025).
Conclusion
These findings support the use of nal-IRI + 5-FU/LV as standard second-line treatment for PC patients after gemcitabine-based chemotherapy. |
Fulltext (714 KB)
.png)
